Retroperitoneal Fibrosis Treatment Market Global Report 2026

The retroperitoneal fibrosis treatment market size has grown strongly in recent years. It will grow from $0.64 billion in 2025 to $0.71 billion in 2026 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to increasing prevalence of autoimmune associated disorders, improvements in advanced imaging accessibility, growing awareness of rare fibrotic diseases, rising adoption of corticosteroid based treatment approaches, expansion of hospital based specialty treatment centers.

The retroperitoneal fibrosis treatment market size is expected to see rapid growth in the next few years. It will grow to $1.04 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing development of targeted biologic therapies, rising integration of AI driven diagnostic support systems, growing demand for minimally invasive interventions, expansion of precision medicine applications, increasing healthcare expenditure for rare disease management. Major trends in the forecast period include rising adoption of personalized immunosuppressive therapy protocols, increasing preference for minimally invasive surgical procedures, growing utilization of early diagnostic imaging approaches, expansion of multidisciplinary care management models, increasing focus on long-term disease monitoring and recurrence prevention.

The increasing incidence of autoimmune diseases is expected to drive the growth of the retroperitoneal fibrosis treatment market in the coming years. Autoimmune diseases are disorders in which the immune system mistakenly targets and damages the body’s own healthy tissues. The prevalence of autoimmune diseases is rising due to increasing exposure to environmental triggers such as pollution and chemical agents. Retroperitoneal fibrosis treatment plays an important role in autoimmune-related conditions by reducing immune-mediated inflammation through therapies such as corticosteroids and immunosuppressants, thereby limiting fibrotic tissue development around the retroperitoneum and preventing complications such as ureteral obstruction. For instance, in August 2024, according to data from Public Health Scotland, a Scotland-based national organization, the Scottish Multiple Sclerosis Register (SMSR) reported 455 newly diagnosed multiple sclerosis cases in 2023. Therefore, the increasing incidence of autoimmune diseases is contributing to the growth of the retroperitoneal fibrosis treatment market.

The increasing healthcare expenditure is expected to support the growth of the retroperitoneal fibrosis treatment market going forward. Healthcare expenditure refers to the overall spending on medical services, treatments, and healthcare resources by governments, insurers, and individuals to provide accessible and high-quality healthcare. Healthcare expenditure is increasing due to the rising burden of chronic diseases, which require prolonged treatment, regular monitoring, continuous medical services, and long-term medication management, resulting in higher overall healthcare costs. Retroperitoneal fibrosis treatment involves substantial long-term healthcare spending due to the requirement for repeated diagnostic imaging, immunosuppressive therapies, surgical procedures, and specialized medical care. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, representing a notable rise compared with the 0.9% growth recorded in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the retroperitoneal fibrosis treatment market.

The growing aging population is expected to drive the growth of the retroperitoneal fibrosis treatment market in the forecast period. An aging population refers to an increase in the share of older individuals within a population due to longer life expectancy and declining birth rates. The aging population is expanding due to advancements in healthcare services and medical technologies that have improved longevity. Retroperitoneal fibrosis treatment is used among elderly patients to manage ureteral obstruction and organ compression through approaches such as corticosteroid therapy, immunosuppressive treatment, and surgical stenting, helping preserve kidney function and manage chronic inflammatory fibrosis associated with age-related immune changes. For instance, in January 2024, according to the Population Reference Bureau, a US-based non-profit organization, the number of Americans aged 65 and above is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% growth. During this period, the share of this age group in the total U.S. population is expected to increase from 17% to 23%. Therefore, the rising aging population is driving the growth of the retroperitoneal fibrosis treatment market.

Major companies operating in the retroperitoneal fibrosis treatment market report are Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca plc, B. Braun SE, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Coloplast A/S, Cook Medical LLC, Eli Lilly and Company, GSK plc, Johnson & Johnson Services Inc., Medtronic plc, Merit Medical Systems Inc., Novartis AG, Olympus Corporation, Pfizer Inc., Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Teleflex Incorporated.

North America was the dominating region in the retroperitoneal fibrosis treatment market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the retroperitoneal fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the retroperitoneal fibrosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.